Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals, Inc. Announces Receptor Discovery Collaboration With Taisho Pharmaceutical Co., Ltd
Arena Pharmaceuticals, Inc. Announces Receptor Discovery Collaboration With Taisho Pharmaceutical Co., Ltd SAN DIEGO, March 26 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has entered into a receptor-discovery research collaboration with Taisho Pharmaceutical
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Completion of Acquisition Of Bunsen Rush Laboratories, Inc
Arena Pharmaceuticals, Inc. Announces Completion of Acquisition Of Bunsen Rush Laboratories, Inc SAN DIEGO, Feb. 20 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the completion of the acquisition of the outstanding capital stock of Bunsen Rush Laboratories,
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Licensing of 'Obesity' Orphan Receptor Target and Small Molecule Modulators
Arena Pharmaceuticals, Inc. Announces Licensing of 'Obesity' Orphan Receptor Target and Small Molecule Modulators SAN DIEGO, Jan. 31 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of an expansion amendment to its May 29, 2000 research agreement with
View HTML
Toggle Summary Arena Pharmaceuticals Announces Profitable Fourth Quarter With Sequential Quarterly Revenue Growth of 76% and Quarterly EPS of $0.05
Arena Pharmaceuticals Announces Profitable Fourth Quarter With Sequential Quarterly Revenue Growth of 76% and Quarterly EPS of $0.05 SAN DIEGO, Jan. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended December 31, 2000.
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Receipt of Second Milestone Payments From Eli Lilly and Company
Arena Pharmaceuticals, Inc. Announces Receipt of Second Milestone Payments From Eli Lilly and Company SAN DIEGO, Jan. 15 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli Lilly
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Expects First Profitable Quarter, Strong Fourth Quarter 2000 Results and Sets Conference Call
<ul><li> First Profitable Quarter</li> <li> Gross Revenue From Collaborations Reaches $4 Million, Up approximately 70% Over Third Quarter Net Income for the Quarter Exceeds $1 Million</li></ul>
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. and Bunsen Rush Laboratories, Inc. Jointly Announce Signing of Letter of Intent & Memorandum of Agreement
Arena Pharmaceuticals, Inc. and Bunsen Rush Laboratories, Inc. Jointly Announce Signing of Letter of Intent &amp; Memorandum of Agreement SAN DIEGO and DALLAS, Dec. 27 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") and Bunsen Rush Laboratories, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Issuance of Notice of Allowance for Drug Discovery Using First Cart-Activated Receptor
Arena Pharmaceuticals, Inc. Announces Issuance of Notice of Allowance for Drug Discovery Using First Cart-Activated Receptor SAN DIEGO, Nov. 29 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of a Notice of Allowance ("Allowance") from the United States
View HTML
Toggle Summary Arena Pharmaceuticals Announces 2000 Third Quarter Results; Sequential Quarterly Revenue Growth of 79%
Arena Pharmaceuticals Announces 2000 Third Quarter Results; Sequential Quarterly Revenue Growth of 79% SAN DIEGO, Oct. 25 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - news ) today reported results for the quarter ended September 30, 2000.
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Achievement Of CART Milestones With Taisho Pharmaceutical Co., Ltd
Arena Pharmaceuticals, Inc. Announces Achievement Of CART Milestones With Taisho Pharmaceutical Co., Ltd SAN DIEGO, Oct. 23 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd.,
View HTML